Publication | Closed Access

Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial

Hematological MalignancyOncologyHigher-risk Myelodysplastic SyndromesMedicineHematologyClinical TrialsMyeloid NeoplasiaUntreated PatientsPharmacotherapyPharmacologyHealth Sciences